Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Durect Corp (DRRX)

Durect Corp (DRRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 36,002
  • Shares Outstanding, K 31,036
  • Annual Sales, $ 8,550 K
  • Annual Income, $ -27,620 K
  • 60-Month Beta 0.94
  • Price/Sales 3.59
  • Price/Cash Flow N/A
  • Price/Book 2.00
Trade DRRX with:

Options Overview Details

View History
  • Implied Volatility 482.04% ( -164.85%)
  • Historical Volatility 105.07%
  • IV Percentile 97%
  • IV Rank 74.19%
  • IV High 646.89% on 05/02/24
  • IV Low 8.12% on 01/03/24
  • Put/Call Vol Ratio 1.41
  • Today's Volume 267
  • Volume Avg (30-Day) 125
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 3,232
  • Open Int (30-Day) 4,533

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.20
  • Low Estimate -0.21
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +61.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7235 +60.33%
on 04/15/24
1.1900 -2.52%
on 05/03/24
+0.0100 (+0.87%)
since 04/03/24
3-Month
0.6802 +70.54%
on 02/07/24
1.4400 -19.44%
on 03/15/24
+0.3110 (+36.63%)
since 02/02/24
52-Week
0.4703 +146.65%
on 11/10/23
7.4600 -84.45%
on 05/22/23
-2.9500 (-71.78%)
since 05/03/23

Most Recent Stories

More News
Durect: Q4 Earnings Snapshot

Durect: Q4 Earnings Snapshot

DRRX : 1.1600 (+17.17%)
Durect: Q3 Earnings Snapshot

Durect: Q3 Earnings Snapshot

DRRX : 1.1600 (+17.17%)
DURECT Corporation Announces Presentations in Upcoming Investor Conferences

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver...

DRRX : 1.1600 (+17.17%)
Durect: Q2 Earnings Snapshot

Durect: Q2 Earnings Snapshot

DRRX : 1.1600 (+17.17%)
DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2023 and provided a corporate update....

DRRX : 1.1600 (+17.17%)
DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver...

DRRX : 1.1600 (+17.17%)
DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the...

DRRX : 1.1600 (+17.17%)
DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company developing epigenetic therapies for the treatment of acute organ injuries and...

DRRX : 1.1600 (+17.17%)
Wall Street Analysts Think Durect (DRRX) Could Surge 594.98%: Read This Before Placing a Bet

The mean of analysts' price targets for Durect (DRRX) points to a 595% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in...

DRRX : 1.1600 (+17.17%)
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of -4% and 41.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

DRRX : 1.1600 (+17.17%)
BVS : 3.97 (+0.25%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Business Summary

Durect Corp. is pioneering the treatment of chronic diseases and conditions by developing and commercializing pharmaceutical systems to deliver the right drug to the right place in the right amount at the right time. Its pharmaceutical systems combine engineering innovations and delivery technology from...

See More

Key Turning Points

3rd Resistance Point 1.4617
2nd Resistance Point 1.3259
1st Resistance Point 1.2429
Last Price 1.1600
1st Support Level 1.0241
2nd Support Level 0.8883
3rd Support Level 0.8053

See More

52-Week High 7.4600
Fibonacci 61.8% 4.7899
Fibonacci 50% 3.9652
Fibonacci 38.2% 3.1404
Last Price 1.1600
52-Week Low 0.4703

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar